Molecular and Cellular Biology of Cancer Program ABSTRACT The mission of the Molecular and Cellular Biology of Cancer (MCBC) Program is to facilitate basic cancer biology research and accelerate the application of basic science discoveries into the clinic for cancer therapeutics and prevention. To achieve this, the Program brings together world-class investigators in the areas of DNA damage response and repair, RNA biology and therapeutics, cancer metabolism, and oncogenic signaling to generate synergy in the war to fight cancer. The scientific themes of the Program are 1) To define the relationship among DNA damage and repair, mutagenesis, and carcinogenesis at the molecular level and to develop therapeutic regimens based on identified targets including molecules involved in DNA damage response, repair, and epigenetic changes; 2) To define and characterize fundamental biological mechanisms for novel microRNAs and long non-coding RNAs in tumor initiation, development, and metastasis as well as to develop technology based on non-coding RNAs for cancer therapeutics; and 3) To elucidate signaling pathway alterations due to metabolic imbalance that result in cancer initiation, cancer cell proliferation and/or death, and metastasis and to improve the design of cancer therapeutic regimens. Targeted recruits who are nationally prominent have brought depth and breadth to the program and include: Drs. Mark LaBarge, Kevin Morris, Zijie Sun, Debbie Thurmond, and Xiaochun Yu. The Program is led by Drs. Binghui Shen, Professor and Chair of Cancer Genetics and Epigenetics, and David Ann, Professor in the Department of Diabetes Complications and Metabolism in the Diabetes and Metabolism Research Institute. In addition to its scientific goals, the MCBC Program seeks to promote inter- and intra-programmatic collaborations, facilitate access to new technologies and resources, create forums for scientific exchange and discussion, discover and elucidate basic cancer processes that can be collaboratively translated to the clinic, and mentor the Program?s junior faculty. Membership: 25 Members representing 11 academic departments Publications: 270 total. 18.5% intra-programmatic; 39.6% inter-programmatic; 28.9% inter-institutional Funding: $8,175,843 peer-reviewed; $3,301,399 of which is NCI funding

Agency
National Institute of Health (NIH)
Institute
National Cancer Institute (NCI)
Type
Center Core Grants (P30)
Project #
5P30CA033572-38
Application #
10059205
Study Section
Subcommittee I - Transistion to Independence (NCI)
Program Officer
Roberson, Sonya
Project Start
1997-08-01
Project End
2022-11-30
Budget Start
2020-12-01
Budget End
2021-11-30
Support Year
38
Fiscal Year
2021
Total Cost
Indirect Cost
Name
Beckman Research Institute/City of Hope
Department
Type
DUNS #
027176833
City
Duarte
State
CA
Country
United States
Zip Code
91010
Liu, Xuxiang; Cao, Minghui; Palomares, Melanie et al. (2018) Metastatic breast cancer cells overexpress and secrete miR-218 to regulate type I collagen deposition by osteoblasts. Breast Cancer Res 20:127
Das, Sadhan; Reddy, Marpadga A; Senapati, Parijat et al. (2018) Diabetes Mellitus-Induced Long Noncoding RNA Dnm3os Regulates Macrophage Functions and Inflammation via Nuclear Mechanisms. Arterioscler Thromb Vasc Biol 38:1806-1820
Querfeld, Christiane; Leung, Samantha; Myskowski, Patricia L et al. (2018) Primary T Cells from Cutaneous T-cell Lymphoma Skin Explants Display an Exhausted Immune Checkpoint Profile. Cancer Immunol Res 6:900-909
Chiuppesi, Flavia; Nguyen, Jenny; Park, Soojin et al. (2018) Multiantigenic Modified Vaccinia Virus Ankara Vaccine Vectors To Elicit Potent Humoral and Cellular Immune Reponses against Human Cytomegalovirus in Mice. J Virol 92:
Petrossian, Karineh; Kanaya, Noriko; Lo, Chiao et al. (2018) ER?-mediated cell cycle progression is an important requisite for CDK4/6 inhibitor response in HR+ breast cancer. Oncotarget 9:27736-27751
Al Malki, Monzr M; Nathwani, Nitya; Yang, Dongyun et al. (2018) Melphalan-Based Reduced-Intensity Conditioning is Associated with Favorable Disease Control and Acceptable Toxicities in Patients Older Than 70 with Hematologic Malignancies Undergoing Allogeneic Hematopoietic Stem Cell Transplantation. Biol Blood Marrow Transplant 24:1828-1835
Bosworth, Alysia; Goodman, Elizabeth L; Wu, Eric et al. (2018) The Minneapolis-Manchester Quality of Life Instrument: reliability and validity of the Adult Form in cancer survivors. Qual Life Res 27:321-332
Vu, Binh Thanh; Shahin, Sophia Allaf; Croissant, Jonas et al. (2018) Chick chorioallantoic membrane assay as an in vivo model to study the effect of nanoparticle-based anticancer drugs in ovarian cancer. Sci Rep 8:8524
Ambaye, Nigus; Chen, Chih-Hong; Khanna, Swati et al. (2018) Streptonigrin Inhibits SENP1 and Reduces the Protein Level of Hypoxia-Inducible Factor 1? (HIF1?) in Cells. Biochemistry 57:1807-1813
Li, Sihui; Ali, Shafat; Duan, Xiaotao et al. (2018) JMJD1B Demethylates H4R3me2s and H3K9me2 to Facilitate Gene Expression for Development of Hematopoietic Stem and Progenitor Cells. Cell Rep 23:389-403

Showing the most recent 10 out of 1396 publications